DonCorleone77 Posted - 1 day ago

$GMAB Citi opens 'positive catalyst watch' on Genmab into data Citi opened a "90-day positive catalyst watch" on shares of Genmab while keeping a Sell rating on the shares. The company's Q1 sales beat consensus and the stock's risk/reward into ASCO is appealing, the analyst tells investors in a research note. The firm says the earnings call commentary that GEN1046 data at ASCO will include overall survival as well as progression free survival data makes for an interesting risk/reward.

Hawaiianinvesta Posted - 1 day ago

$GMAB stellar results, anything under 3 is an absolute steal

DonCorleone77 Posted - 1 day ago

$GMAB Genmab maintaining 2024 financial guidance Genmab is maintaining its 2024 financial guidance published on February 14, the company noted. Genmab said: "Following the announcement of the proposed acquisition of ProfoundBio, Genmab's operating expenses before expenses incurred by it in connection with the proposed transaction are now anticipated to be at or moderately above the upper end of the previously disclosed guidance range of DKK 12.4 -13.4B. The anticipated increase reflects the incremental R&D investment to support the advancement of ProfoundBio's clinical programs, primarily Rina-S. Genmab's revenue guidance is unchanged and expected to be in the previously disclosed guidance range of DKK 18.7 - 20.5B. We expect to update our guidance no later than in connection with our second quarter 2024 earnings."

DonCorleone77 Posted - 1 day ago

$GMAB $JNJ $NVS $ABBV $PFE Genmab reports Q1 revenue increased 46% vs. last year Revenue was DKK 4.143B for the first three months of 2024. compared to DKK 2.834B for the first three months of 2023. The increase of DKK 1.309B, or 46%, was primarily driven by higher Darzalex and Kesimpta royalties achieved under collaborations with Janssen (JNJ) and Novartis Pharma (NVS), respectively, EPKINLY net product sales, and a milestone achieved under the company's collaboration with AbbVie (ABBV), Genmab (GMAB) stated. Operating profit was DKK 801M in the first three months of 2024, compared to DKK 417M in the first three months of 2023. "The acceptance for Priority Review by the U.S. FDA of the sBLAs for EPKINLY and Tivdak that we received in the first quarter are important events that support our commitment to continue to deliver innovative treatment options that have the potential to profoundly impact the lives of patients. These regulatory acceptances for priority review also reflect our dedication to working with our partners, AbbVie Inc. and Pfizer Inc. to expand the labels for EPKINLY and Tivdak, respectively, in order to maximize the potential of both medicines and bring them to as many patients in need of alternative therapeutic options as possible," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

trizzle Posted - 04/30/24

$GMAB do we hit $40 this quarter? Good earnings may help

Source65 Posted - 04/29/24

$GMAB This baby bout to fly ..great announcement today and earnings on deck this week

DonCorleone77 Posted - 04/29/24

$GMAB $PFE Genmab-Pfizer gain full FDA approval for TIVDAK in Metastatic Cervical Cancer Pfizer (PFE) and Genmab A/S (GMAB) "announced the FDA approves the supplemental Biologics License Application granting full approval for TIVDAK, or tisotumab vedotin-tftv, for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. The approval is based on results from the global, randomized, Phase 3 innovaTV 301 clinical trial, which met its primary endpoint, demonstrating overall survival benefit in adult patients with previously treated recurrent or metastatic cervical cancer treated with TIVDAK compared to chemotherapy. Secondary endpoints of progression-free survival (PFS) and confirmed objective response rate were also met. In October 2023, results from the innovaTV 301 study were presented during the Presidential session at the European Society of Medical Oncology Congress. The innovaTV 301 study demonstrated a 30% reduction in the risk of death compared to chemotherapy. Median OS for patients treated with TIVDAK was 11.5 months versus chemotherapy 9.5 months."

Stock_Titan Posted - 04/29/24

$GMAB $PFE TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer https://www.stocktitan.net/news/GMAB/tivdak-r-tisotumab-vedotin-tftv-receives-u-s-fda-approval-to-treat-byw43lzntzn0.html

Stock_Titan Posted - 04/29/24

$PFE $GMAB FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer https://www.stocktitan.net/news/PFE/fda-grants-full-approval-for-tivdak-r-to-treat-recurrent-or-uj9srfbbgi3n.html

Gutsman Posted - 04/25/24

$GMAB Earnings on the 2nd, on the FDA calendar the week after. Looks like it is time to start buying shares

G101SPM Posted - 04/22/24

$GMAB $28.70 bid. DAC (dollar average cost) $29.52 (4.17.24). EXIT $40.00. UPDATE: On March 15, 2024, Genmab(GMAB) announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. ^ Transactions April 15, 2024 to April 19, 2024: Total 32,701 1,984.26 64,887,132.57 Total 39,367 281,116,033.75 Accumulated 408,701 836,159,512.12 Following these transactions, Genmab(GMAB) holds 1,269,043 shares as treasury shares, corresponding to 1.92% of the total share capital and voting rights.

G101SPM Posted - 04/16/24

$GMAB $29.52 bid. BUY/NEW LONG POSITION carries SPM 87.86 tag to $40 EXIT.

CDMO Posted - 04/16/24

$GMAB 23% increased darzalex sales YoY for JnJ, nice increase in royalties for genmab

ViractaTrader77 Posted - 04/15/24

No brainer acquisition for a big pharma for a billion dollars in equity for Sutro Biopharma. Nextgen $IMGN adc which was cornerstone of $ABBV deal- drug similar warhead. Tons of partnership money flowing in from Astellas and Ispen Pharma. Treasure trove of cash… this won’t last long….$STRO $GMAB just paid $1.8 billion for similar drug… easy 4x upside

trizzle Posted - 04/09/24

$GMAB come on. Great profits, growing pipeline, boring investment. At least pay a dividend if going to be this pathetic. Should be 40-50 this year.

CDMO Posted - 04/08/24

$GMAB tempted to add here once again

HoHoHoHum Posted - 1 month ago

$GMAB been looking at this after yesterdays acquisition news. company has great cash flow excellent balance sheet and a solid promising pipeline. has the potential to hit 100 in 3-4 years.

tradethehalt Posted - 1 month ago

$GMAB Genmab Expands Oncology Portfolio with $1.8 Billion ProfoundBio Acquisition. https://www.reuters.com/markets/deals/denmarks-genmab-acquire-profoundbio-18-billion-2024-04-03/

Stock_Titan Posted - 1 month ago

$GMAB Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio https://www.stocktitan.net/news/GMAB/genmab-to-broaden-and-strengthen-oncology-portfolio-with-acquisition-oxr2p2kn7l8u.html

CDMO Posted - 1 month ago

$GMAB just an article about gmab https://www.fiercepharma.com/pharma/genmab-nabs-lease-us-expansion-it-looks-boost-marketing-its-abbvie-partnered-lymphoma-med

Digital_Waffle_Pirate Posted - 03/30/24

$GMAB interesting

trizzle Posted - 03/27/24

$GMAB nevermind they disappoint again. I don’t know what their problem is. Over $4B in profit last year and this is the trend for shareholders. Really pathetic. Should be 40+ now

trizzle Posted - 03/26/24

$GMAB ok ok ok

ians Posted - 03/22/24

$LVTX Baby $GMAB has $6.80 Ave WS PT 👍☘️

trizzle Posted - 03/18/24

$GMAB Danish leadership keeps this very Un-exciting

LiveWell57 Posted - 03/15/24

$GMAB New discovery for me. The technology certainly has captured my interest. Let’s see if the financials keep my interest. Nuetral

trizzle Posted - 03/13/24

$GMAB strength all of a sudden. Ok we will take it.

CDMO Posted - 03/11/24

$GMAB finally

trizzle Posted - 03/07/24

$GMAB moon soon?

S_lalle Posted - 03/06/24

$GMAB Johnson & Johnson submits application to the European Medicines Agency for DARZALEX® (daratumumab)-based quadruplet therapy for the treatment of patients with transplant-eligible, newly diagnosed multiple myeloma / PERSEUS